Solasia PharmaSolasia Pharma K.K.4597東証グロース医薬品FY ending Dec 2023, consolidated, IFRS

Solasia Pharma FY ending Dec 2021 results

Solasia Pharma brought in ¥559M in revenue.

Revenue changed +75.8% from the prior year.

What changed from last year

FY ending Dec 2018 → FY ending Dec 2021

FY ending Dec 2018 → FY ending Dec 2021

※ Cost of revenue is not disclosed; expenses are combined

※ Operating income is not disclosed; the chart goes straight to pretax income including investment gains

A machine-readable operating income value exists, but it is not in the validated published data, so the chart is omitted.

Show source documents (4)

EDINET (FSA Japan)
有価証券報告書－第18期(2025/01/01－2025/12/31)
ID S100XT682026-03-24Open
EDINET (FSA Japan)
有価証券報告書－第15期(2022/01/01－2022/12/31)
ID S100QFP52023-03-23Open
EDINET (FSA Japan)
有価証券報告書－第14期(令和3年1月1日－令和3年12月31日)
ID S100NQ7L2022-03-24Open
EDINET (FSA Japan)
有価証券報告書－第13期(令和2年1月1日－令和2年12月31日)
ID S100L2ET2021-03-29Open

Extracted from XBRL: 9 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.